Nexavar Plus Paclitaxel Show Progression Free Survival By 74%
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals have announced results from a randomised, placebo-controlled phase 2 trial sponsored by Northwestern University. The study, which evaluated Nexavar (sorafenib) tablets in
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.